5 News & Press Releases found
Bristol Myers Squibb Corporate News
-
Bristol Myers Squibb to Highlight Long-Term Growth Strategy at J.P. Morgan’s 40th Annual Healthcare Conference
Bristol Myers Squibb (NYSE:BMY) will highlight progress against the Company’s growth strategy and outlook for 2022 during a presentation scheduled today at 7:30 a.m. ET at the 40th Annual J.P. Morgan Healthcare Conference. “We ...
-
Bristol Myers Squibb Receives Positive CHMP Opinion for CAR T Cell Therapy Breyanzi (lisocabtagene maraleucel) for Relapsed or Refractory DLBCL, PMBCL and FL3B
Bristol Myers Squibb (NYSE: BMY) today announced the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended approval of Breyanzi (lisocabtagene maraleucel; liso-cel), a ...
-
Bristol Myers Squibb (NYSE: BMY) today announced the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended approval of Breyanzi (lisocabtagene maraleucel; liso-cel), a CD19-directed chimeric antigen
Bristol-Myers Squibb K.K. today announced that Japan’s Ministry of Health, Labour and Welfare has approved Abecma (idecabtagene vicleucel), a B-cell maturation antigen (BCMA)-directed chimeric antigen receptor (CAR) T cell ...
-
Century Therapeutics and Bristol Myers Squibb Enter into a Strategic Collaboration to Develop iPSC-derived Allogeneic Cell Therapies
Century Therapeutics (NASDAQ: IPSC) and Bristol Myers Squibb (NYSE: BMY) announced today a research collaboration and license agreement (the “agreement”) to develop and commercialize up to four induced pluripotent ...
-
Bristol Myers Squibb to Present at J.P. Morgan’s 40th Annual Healthcare Conference
Bristol Myers Squibb (NYSE: BMY) today announced that the company will present at J.P. Morgan’s 40th Annual Virtual Healthcare Conference on Monday, January 10, 2022. Giovanni Caforio, M.D., Board Chair and Chief Executive ...